Results 31 to 40 of about 908,554 (203)

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy [PDF]

ESMO Gastrointestinal Oncology
Background: Currently, mismatch repair deficient/microsatellite instable (dMMR/MSI) status constitutes a validated predictive marker of response to immune checkpoint inhibitors (ICIs) in patients with metastatic colorectal cancer (mCRC).
M. Svrcek, A. Cayre, T. Samaille, R. Colle, L. Mas, P. Bourgoin, E. Guillerm, R. Cohen, F. Penault-Llorca, T. André, N. Radosevic-Robin   +10 more
doaj   +2 more sources

The promise of TRK inhibitors in pediatric cancers with NTRK fusions. [PDF]

Cancer Genet, 2022
Blauel ER, Laetsch TW.
europepmc   +2 more sources

The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer. [PDF]

Cancer Genet, 2022
Ricarte-Filho JC, Halada S, O'Neill A, Casado-Medrano V, Laetsch TW, Franco AT, Bauer AJ.   +6 more
europepmc   +2 more sources

NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives. [PDF]

Cancer Genet, 2022
Casado-Medrano V, O'Neill A, Halada S, Laetsch TW, Bauer AJ, Franco AT.   +5 more
europepmc   +2 more sources

Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. [PDF]

Cancer Genet, 2022
Saliba J, Church AJ, Rao S, Danos A, Furtado LV, Laetsch T, Zhang L, Nardi V, Lin WH, Ritter DI, Madhavan S, Li MM, Griffith OL, Griffith M, Raca G, Roy A.   +15 more
europepmc   +2 more sources

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. [PDF]

Am J Surg Pathol, 2017
Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA.   +10 more
europepmc   +2 more sources

Pediatric NTRK fusion sarcomas [PDF]

Diagnostic Pathology, 2020
Abstract Background While ETV6-NTRK3 fusion is common in infantile fibrosarcoma, NTRK1 fusion in pediatric sarcoma is extremely rare and consequently not well known. Herein, we evaluated NTRK1 fusion pediatric sarcomas to determine their clinicopathological nature and differential diagnosis from classic ETV6-NTRK3 fusion infantile fibrosarcoma.
Jeongwan Kang, Jin Woo Park, Jae-Kyung Won, Jeong Mo Bae, Hongseok Yun, Seung-Ki Kim, Jung Yoon Choi, Hyoung Jin Kang, Joo Heon Shin, Sung-Hye Park   +9 more
  +6 more sources

Ntrk gene fusion detection in atypical spitz tumors [PDF]

International Journal of Molecular Sciences, 2021
Atypical Spitz tumors (AST) deviate from stereotypical Spitz nevi for one or more atypical features and are now regarded as an intermediate category of melanocytic tumors with uncertain malignant potential. Activating NTRK1/NTRK3 fusions elicit oncogenic events in Spitz lesions and are targetable with kinase inhibitors.
Castiglione, F., Senetta, R.
core   +5 more sources

NTRK fusion in Japanese colorectal adenocarcinomas [PDF]

Scientific Reports, 2021
AbstractNTRK fusion-positive tumors are known to be highly sensitive to TRK inhibitors, such as larotrectinib and entrectinib. Therefore, identification of patients who can potentially benefit from these inhibitors is important; however, the frequency of NTRK fusions in Japanese patients with colorectal cancer (CRC) is unknown.
Yuya Yamashiro, Taisei Kurihara, Takuo Hayashi, Yoshiyuki Suehara, Takashi Yao, Shunsuke Kato, Tsuyoshi Saito   +6 more
openaire   +3 more sources

Primary and Metastatic Melanoma With NTRK Fusions. [PDF]

Am J Surg Pathol, 2018
A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and ...
Lezcano C, Shoushtari AN, Ariyan C, Hollmann TJ, Busam KJ.   +4 more
europepmc   +4 more sources